Clinical Trials · NCT05440383
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Enrollment
- 287
- Start date
- Oct 2022
- Locations
- 1 site, Japan
- Primary endpoint
- Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administration